Screener / SEC EDGAR /CIK 0001832466 /10-K filed Feb 27, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Financials · Health Insurance

Alignment Healthcare, Inc. ALHC

Compare with peers Embed
Earnings releases

Latest results release: Oct 29, 2026

8-K item 2.02, exhibit 99

What ALHC's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Oct 29, 2026 · EX-99.1

Alignment Healthcare Reports Third Quarter 2026 Results, Updates Full-Year

Open on SEC

EXHIBIT 99.1 Alignment Healthcare Reports Third Quarter 2026 Results, Updates Full-Year Outlook ORANGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today reported financial results for its third quarter ended Sept. 30, 2026.

“Our third-quarter membership and revenue growth demonstrate continued demand for Alignment’s products and services, while medical trends ran higher than expected,” said John Kao, chairman and CEO. “We are taking a prudent approach to the fourth quarter and lowering our outlook based on current headwinds. Our revised guidance does not assume any benefit from the actions underway. We are confident we can deliver against these expectations. Our focus now is on execution and taking the steps necessary to drive more consistent performance as we scale and deliver profitable growth over the long term.”

Third Quarter 2026 Financial Highlights All comparisons, unless otherwise noted, are to the three months endedSeptember 30, 2025.

* Please see “Third Quarter 2026 Non-GAAP Reconciliation Tables” below for more information on the non-GAAP financial measures reported here as supplemental information.

Outlook for Fourth Quarter and Fiscal Year 2026 Full-year health plan membership and revenue guidance was raised to reflect continued sales momentum, while adjusted gross profit and adjusted EBITDA guidance was lowered to reflect higher medical costs experienced during the third quarter.

Three Months Twelve Months Ending Ending December 31, 2026 December 31, 2026 ────────────────────────────────────────────────────────────────────────────── $ Millions No Less Than No Less Than Health Plan 305,000 305,000 Membership Revenue $1,316 $5,245 Adjusted Gross $104 $575 Profit(1) Adjusted $(28) $100 EBITDA(1) Adjusted gross profit and adjusted EBITDA are non-GAAP financial measures presented as supplemental disclosure. We cannot provide estimated ranges for the most directly comparable GAAP measures without unreasonable efforts because of the uncertainty (1) around certain items that may impact such GAAP measures, including equity-based compensation expense and depreciation and amortization, that are not within our control or cannot be reasonably predicted. See “Third Quarter 2026 Non-GAAP Reconciliation Tables” for additional information.

Thr… Nine Mon… Mont… End… Ended (d… Sep… Sept… in 30, 30, th… 2026 2025 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net in… $ (8,0… ) $ 3,7… $ 39,… $ 10,0… (l… Le… Net lo… at… — — — (254 ) to no… in… Ad… Inte… 4,280 3,9… 12,… 11,8… expe… Depr… and 8,115 7,9… 23,… 22,6… amor… Inco… tax (22 ) 2 1,2… 3,247 expe… Equi… 17,4… 16,… 49,… 48,9… comp… Liti… — 546 481 1,608 cost… Gain on sale of — — (1 ) (72 ) prop… and equi… Ad… $ 21,8… $ 32,… $ 127… $ 98,5… EB… Adju… EBIT… is a non-… fina… meas… that is pres… as supp… disc… that we defi… as net inco… (los… befo… inte… (1) expe… inco… taxe… depr… and amor… expe… cert… liti… cost… gains or loss… on sale of prop… and equi… and equi… comp… expe… Amor… expe… for the nine mont… ended Sept… 30, 2025 incl… $0.6 mill… in impa… expe… rela… to the reme… (2) of good… asso… with one of our subs… There was no impa… expe… for the three mont… ended Sept… 30, 2025. Repr… equi… comp… rela… to (3) gran… made in the appl… year. Repr… liti… costs cons… outs… of the ordi… cour… of busi… based on the foll… cons… which we asse… regu… (i) the freq… of simi… cases that have been brou… to date, or (4) are expe… to be brou… with… two year… (ii) comp… of the case, (iii) natu… of the reme… soug… (iv) liti… post… of the Comp… (v) coun… invo… and (vi) the Comp… over… liti… stra…

Conference Call Details The company will host a conference call at 5 p.m. EDT today to discuss these results and management’s outlook for future financial and operational performance. A live audio webcast will be available online at https://ir.alignmenthealth.com/. At the start of the conference call, participants may access the webcast at the following link: . A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web links, and will remain available for approximately 12 months.

About Alignment Health Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health’s mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members every day. Based in California, the company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit .

Forward-Looking Statements This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and our financial outlook for the quarter and year ending Dec. 31, 2026. Forward-looking statements are subject to risks and uncertainties and are based on assumptions that may prove to be inaccurate, which could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully execute our business plan and achieve anticipated operational improvements and financial results; our ability to manage changes in medical costs and healthcare utilization, and our ability to accurately estimate, price for and manage such costs and utilization; our ability to attract new members and enter new markets, including the need for certain governmental approvals; our ability to achieve and maintain a high rating for our plans on the Five Star Quality Rating System; our ability to develop and maintain satisfactory relationships with care providers that service our members; risks associated with being a government contractor, including potential federal reductions in MA funding; changes in laws and regulations applicable to our business model; risks related to our indebtedness; changes in market or industry conditions and receptivity to our technology and services; results of litigation or a security incident; and the impact of shortages of qualified personnel and related increases in our labor costs. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and the other periodic reports we file with the SEC. All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.

Condensed Consolidated Balance Sheets (in thousands, except par value and share amounts) September 30, December 31, (Unaudited) 2026 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current Assets: Cash and cash equivalents $ 727,694 $ 575,817 Accounts receivable (less allowance for credit losses of 242,545 253,207 $699 at September 30, 2026 and $833 at December 31, 2025) Investments - current 15,260 28,413 Prepaid expenses and other current 192,808 94,140 assets Total current assets 1,178,307 951,577 Property and equipment, net 66,439 64,251 Right of use asset, net 7,206 7,019 Goodwill 32,060 32,060 Intangible assets, net 4,550 4,550 Other assets 8,301 6,329 Total assets $ 1,296,863 $ 1,065,786 Liabilities and Stockholders' Equity Current Liabilities: Medical expenses payable $ 621,746 $ 474,569 Accounts payable and accrued 34,562 33,284 expenses Accrued compensation 32,744 49,013 Total current liabilities 689,052 556,866 Long-term debt, net of debt issuance 324,497 323,176 costs Long-term portion of lease 6,202 6,467 liabilities Total liabilities 1,019,751 886,509 Stockholders' Equity: Preferred stock, $0.001 par value; 100,000,000 shares authorized as of September 30, 2026 and December — — 31, 2025, respectively; no shares issued and outstanding as of September 30, 2026 and December 31, 2025 Common stock, $0.001 par value; 1,000,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 209,152,387 and 209 205 204,153,619 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively Additional paid-in capital 1,245,996 1,188,089 Accumulated deficit (969,093 ) (1,009,017 ) Total stockholders' equity 277,112 179,277 Total liabilities and stockholders' $ 1,296,863 $ 1,065,786 equity

Condensed Consolidated Statements of Cash Flows (in thousands) (Unaudited) Nine Months Ended Operating September 30, Activities: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 39,924 $ 10,028 Adjustments to reconcile net income to net cash provided by operating activities: Provision for credit 699 548 loss Gain on sale of property and (1 ) (72 ) equipment Depreciation and 23,834 22,648 amortization Amortization-invest… (478 ) (1,041 ) discount Amortization-debt 1,790 1,321 issuance costs Equity-based 49,680 48,967 compensation Non-cash lease 1,439 1,178 expense Changes in operating assets and liabilities: Accounts receivable 9,963 (66,451 ) Prepaid expenses and other current (98,668 ) (84,326 ) assets Other assets (9 ) (47 ) Medical expenses 147,177 239,008 payable Accounts payable and 1,004 11,185 accrued expenses Accrued compensation (16,269 ) 8,349 Lease liabilities (1,690 ) (993 ) Net cash provided by operating 158,395 190,302 activities Investing Activities: Purchase of (32,510 ) (45,194 ) investments Sale of property and — 75 equipment Maturities of 46,135 57,995 investments Sale of business — 1,065 Acquisition of property and (25,952 ) (21,752 ) equipment Net cash used in (12,327 ) (7,811 ) investing activities Financing Activities: Debt issuance costs (2,397 ) (26 ) Proceeds from stock 8,231 2,771 option exercises Net cash provided by financing 5,834 2,745 activities Net increase in cash 151,902 185,236 Cash, cash equivalents and restricted 577,937 434,942 cash at beginning of period Cash, cash equivalents and restricted $ 729,839 $ 620,178 cash at end of period Supplemental disclosure of cash flow information: Cash paid for $ 7,013 $ 6,740 interest Supplemental non-cash investing and financing activities: Acquisition of property in accounts $ 9 $ 79 payable

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the total above:

Certain of these financial measures are considered “non-GAAP” financial measures within the meaning of Item 10 of Regulation S-K promulgated by the SEC. We believe that non-GAAP financial measures provide an additional way of viewing aspects of our operations that, when viewed with the GAAP results, provide a more complete understanding of our results of operations and the factors and trends affecting our business. These non-GAAP financial measures are also used by our management to evaluate financial results and to plan and forecast future periods. However, non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Non-GAAP financial measures used by us may differ from the non-GAAP measures used by other companies, including our competitors. To supplement our consolidated financial statements presented on a GAAP basis, we disclose the following non-GAAP measures: Medical Benefits Ratio, Adjusted EBITDA and Adjusted Gross Profit as these are performance measures that our management uses to assess our operating performance. Because these measures facilitate internal comparisons of our historical operating performance on a more consistent basis, we use these measures for business planning purposes and in evaluating acquisition opportunities.

Adjusted EBITDA is a non-GAAP financial measure that we define as net income (loss) before interest expense, income taxes, depreciation and amortization expense, certain litigation costs, gains or losses on sale of property and equipment, and equity-based compensation expense.

Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of Adjusted EBITDA in lieu of net income (loss), which is the most directly comparable financial measure calculated in accordance with GAAP.

Our use of the term Adjusted EBITDA may vary from the use of similar terms by other companies in our industry and accordingly may not be comparable to similarly titled measures used by other companies.

We calculate our MBR by dividing total medical expenses, excluding depreciation, and medical equity-based compensation, by total revenues in a given period.

Adjusted gross profit is a non-GAAP financial measure that we define as income (loss) from operations before depreciation and amortization, medical equity- based compensation expense, and selling, general, and administrative expenses.

Adjusted gross profit should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of adjusted gross profit in lieu of income (loss) from operations, which is the most directly comparable financial measure calculated in accordance with GAAP.

Our use of the term adjusted gross profit may vary from the use of similar terms by other companies in our industry and accordingly may not be comparable to similarly titled measures used by other companies.

Full text with the tables
                                                                    EXHIBIT 99.1
   Alignment Healthcare Reports Third Quarter 2026 Results, Updates Full-Year   
                                    Outlook                                     
ORANGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc.
(NASDAQ: ALHC), today reported financial results for its third quarter ended
Sept. 30, 2026.

“Our third-quarter membership and revenue growth demonstrate continued demand
for Alignment’s products and services, while medical trends ran higher than
expected,” said John Kao, chairman and CEO. “We are taking a prudent approach to
the fourth quarter and lowering our outlook based on current headwinds. Our
revised guidance does not assume any benefit from the actions underway. We are
confident we can deliver against these expectations. Our focus now is on
execution and taking the steps necessary to drive more consistent performance as
we scale and deliver profitable growth over the long term.”

Third Quarter 2026 Financial Highlights
All comparisons, unless otherwise noted, are to the three months endedSeptember
30, 2025.

* Please see “Third Quarter 2026 Non-GAAP Reconciliation Tables” below for more
information on the non-GAAP financial measures reported here as supplemental
information.

Outlook for Fourth Quarter and Fiscal Year 2026
Full-year health plan membership and revenue guidance was raised to reflect
continued sales momentum, while adjusted gross profit and adjusted EBITDA
guidance was lowered to reflect higher medical costs experienced during the
third quarter.
                                                                                
                                            Three Months         Twelve Months  
                                                  Ending                Ending  
                                       December 31, 2026     December 31, 2026  
 ────────────────────────────────────────────────────────────────────────────── 
  $ Millions                                No Less Than          No Less Than  
  Health Plan                                    305,000               305,000  
  Membership                                                                    
  Revenue                                         $1,316                $5,245  
  Adjusted Gross                                    $104                  $575  
  Profit(1)                                                                     
  Adjusted                                         $(28)                  $100  
  EBITDA(1)                                                                     
                    Adjusted gross                                              
                    profit and                                                  
                    adjusted EBITDA                                             
                    are non-GAAP                                                
                    financial                                                   
                    measures                                                    
                    presented as                                                
                    supplemental                                                
                    disclosure. We                                              
                    cannot provide                                              
                    estimated ranges                                            
                    for the most                                                
                    directly                                                    
                    comparable GAAP                                             
                    measures without                                            
                    unreasonable                                                
                    efforts because                                             
                    of the                                                      
                    uncertainty                                                 
  (1)               around certain                                              
                    items that may                                              
                    impact such GAAP                                            
                    measures,                                                   
                    including                                                   
                    equity-based                                                
                    compensation                                                
                    expense and                                                 
                    depreciation and                                            
                    amortization,                                               
                    that are not                                                
                    within our                                                  
                    control or cannot                                           
                    be reasonably                                               
                    predicted. See                                              
                    “Third Quarter                                              
                    2026 Non-GAAP                                               
                    Reconciliation                                              
                    Tables” for                                                 
                    additional                                                  
                    information.                                                
                                                                                
Third Quarter 2026 Non-GAAP Reconciliation Tables

Adjusted Gross Profit is reconciled as follows:
                                                                                
               Three                             Nine                           
               Mont…                             Months                         
               Ended                             Ended                          
  (do…         Sept…                             Septe…                         
  in           30,                               30,                            
  tho…         2026               2025           2026             2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Inc…                                                                          
  (lo…         $      (3,7…  )    $     7,681    $       53,8…    $     25,036  
  from                                                                          
  ope…                                                                          
  Add                                                                           
  bac…                                                                          
        Equi…                                                                   
        comp…         1,511             1,775            4,815           4,521  
        (med…                                                                   
        expe…                                                                   
        Depr…                                                                   
        (med…             7                 8               33              74  
        expe…                                                                   
        Depr…                                                                   
        and           8,108             7,977            23,8…          22,574  
        amor…                                                                   
        Sell…                                                                   
        gene…                                                                   
        and           136,…             110,…            388,…          317,6…  
        admi…                                                                   
        expe…                                                                   
        Total                                                                   
        add           145,…             119,…            417,…          344,8…  
        back                                                                    
  Adj…                                                                          
  gro…         $      142,…       $     127,…    $       470,…    $     369,8…  
  pro…                                                                          
        Adju…                                                                   
        gross                                                                   
        prof…                                                                   
        is a                                                                    
        non-…                                                                   
        fina…                                                                   
        meas…                                                                   
        that                                                                    
        is                                                                      
        pres…                                                                   
        as                                                                      
        supp…                                                                   
        disc…                                                                   
        that                                                                    
        we                                                                      
        defi…                                                                   
        as                                                                      
  (1)   inco…                                                                   
        (los…                                                                   
        from                                                                    
        oper…                                                                   
        befo…                                                                   
        depr…                                                                   
        and                                                                     
        amor…                                                                   
        medi…                                                                   
        equi…                                                                   
        comp…                                                                   
        expe…                                                                   
        and                                                                     
        sell…                                                                   
        gene…                                                                   
        and                                                                     
        admi…                                                                   
        expe…                                                                   
        Amor…                                                                   
        expe…                                                                   
        for                                                                     
        the                                                                     
        nine                                                                    
        mont…                                                                   
        ended                                                                   
        Sept…                                                                   
        30,                                                                     
        2025,                                                                   
        incl…                                                                   
        $0.6                                                                    
        mill…                                                                   
        in                                                                      
        impa…                                                                   
        expe…                                                                   
        rela…                                                                   
        to                                                                      
        the                                                                     
        reme…                                                                   
  (2)   of                                                                      
        good…                                                                   
        asso…                                                                   
        with                                                                    
        one                                                                     
        of                                                                      
        our                                                                     
        subs…                                                                   
        There                                                                   
        was                                                                     
        no                                                                      
        impa…                                                                   
        expe…                                                                   
        for                                                                     
        the                                                                     
        three                                                                   
        mont…                                                                   
        ended                                                                   
        Sept…                                                                   
        30,                                                                     
        2025.                                                                   
                                                                                
Adjusted EBITDA is reconciled as follows:
                                                                                
              Thr…                            Nine                              
              Mon…                            Mont…                             
              End…                            Ended                             
  (d…         Sep…                            Sept…                             
  in          30,                             30,                               
  th…         2026              2025          2026              2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  in…         $     (8,0…  )    $     3,7…    $      39,…       $     10,0…     
  (l…                                                                           
  Le…                                                                           
  Net                                                                           
  lo…                                                                           
  at…                   —                —              —              (254  )  
  to                                                                            
  no…                                                                           
  in…                                                                           
  Ad…                                                                           
       Inte…        4,280             3,9…           12,…             11,8…     
       expe…                                                                    
       Depr…                                                                    
       and          8,115             7,9…           23,…             22,6…     
       amor…                                                                    
       Inco…                                                                    
       tax            (22  )             2           1,2…             3,247     
       expe…                                                                    
       Equi…        17,4…             16,…           49,…             48,9…     
       comp…                                                                    
       Liti…            —              546            481             1,608     
       cost…                                                                    
       Gain                                                                     
       on                                                                       
       sale                                                                     
       of               —                —             (1  )            (72  )  
       prop…                                                                    
       and                                                                      
       equi…                                                                    
  Ad…         $     21,8…       $     32,…    $      127…       $     98,5…     
  EB…                                                                           
       Adju…                                                                    
       EBIT…                                                                    
       is a                                                                     
       non-…                                                                    
       fina…                                                                    
       meas…                                                                    
       that                                                                     
       is                                                                       
       pres…                                                                    
       as                                                                       
       supp…                                                                    
       disc…                                                                    
       that                                                                     
       we                                                                       
       defi…                                                                    
       as                                                                       
       net                                                                      
       inco…                                                                    
       (los…                                                                    
       befo…                                                                    
       inte…                                                                    
  (1)  expe…                                                                    
       inco…                                                                    
       taxe…                                                                    
       depr…                                                                    
       and                                                                      
       amor…                                                                    
       expe…                                                                    
       cert…                                                                    
       liti…                                                                    
       cost…                                                                    
       gains                                                                    
       or                                                                       
       loss…                                                                    
       on                                                                       
       sale                                                                     
       of                                                                       
       prop…                                                                    
       and                                                                      
       equi…                                                                    
       and                                                                      
       equi…                                                                    
       comp…                                                                    
       expe…                                                                    
       Amor…                                                                    
       expe…                                                                    
       for                                                                      
       the                                                                      
       nine                                                                     
       mont…                                                                    
       ended                                                                    
       Sept…                                                                    
       30,                                                                      
       2025                                                                     
       incl…                                                                    
       $0.6                                                                     
       mill…                                                                    
       in                                                                       
       impa…                                                                    
       expe…                                                                    
       rela…                                                                    
       to                                                                       
       the                                                                      
       reme…                                                                    
  (2)  of                                                                       
       good…                                                                    
       asso…                                                                    
       with                                                                     
       one                                                                      
       of                                                                       
       our                                                                      
       subs…                                                                    
       There                                                                    
       was                                                                      
       no                                                                       
       impa…                                                                    
       expe…                                                                    
       for                                                                      
       the                                                                      
       three                                                                    
       mont…                                                                    
       ended                                                                    
       Sept…                                                                    
       30,                                                                      
       2025.                                                                    
       Repr…                                                                    
       equi…                                                                    
       comp…                                                                    
       rela…                                                                    
       to                                                                       
  (3)  gran…                                                                    
       made                                                                     
       in                                                                       
       the                                                                      
       appl…                                                                    
       year.                                                                    
       Repr…                                                                    
       liti…                                                                    
       costs                                                                    
       cons…                                                                    
       outs…                                                                    
       of                                                                       
       the                                                                      
       ordi…                                                                    
       cour…                                                                    
       of                                                                       
       busi…                                                                    
       based                                                                    
       on                                                                       
       the                                                                      
       foll…                                                                    
       cons…                                                                    
       which                                                                    
       we                                                                       
       asse…                                                                    
       regu…                                                                    
       (i)                                                                      
       the                                                                      
       freq…                                                                    
       of                                                                       
       simi…                                                                    
       cases                                                                    
       that                                                                     
       have                                                                     
       been                                                                     
       brou…                                                                    
       to                                                                       
       date,                                                                    
       or                                                                       
  (4)  are                                                                      
       expe…                                                                    
       to be                                                                    
       brou…                                                                    
       with…                                                                    
       two                                                                      
       year…                                                                    
       (ii)                                                                     
       comp…                                                                    
       of                                                                       
       the                                                                      
       case,                                                                    
       (iii)                                                                    
       natu…                                                                    
       of                                                                       
       the                                                                      
       reme…                                                                    
       soug…                                                                    
       (iv)                                                                     
       liti…                                                                    
       post…                                                                    
       of                                                                       
       the                                                                      
       Comp…                                                                    
       (v)                                                                      
       coun…                                                                    
       invo…                                                                    
       and                                                                      
       (vi)                                                                     
       the                                                                      
       Comp…                                                                    
       over…                                                                    
       liti…                                                                    
       stra…                                                                    
                                                                                
Conference Call Details
The company will host a conference call at 5 p.m. EDT today to discuss these
results and management’s outlook for future financial and operational
performance. A live audio webcast will be available online at
https://ir.alignmenthealth.com/. At the start of the conference call,
participants may access the webcast at the following link: . A replay of the
call will be available via webcast for on-demand listening shortly after the
completion of the call, at the same web links, and will remain available for
approximately 12 months.

About Alignment Health
Alignment Health is championing a new path in senior care that empowers members
to age well and live their most vibrant lives. A consumer brand name of
Alignment Healthcare (NASDAQ: ALHC), Alignment Health’s mission-focused team
makes high-quality, low-cost care a reality for its Medicare Advantage members
every day. Based in California, the company partners with nationally recognized
and trusted local providers to deliver coordinated care, powered by its
customized care model, 24/7 concierge care team and purpose-built technology,
AVA. As it expands its offerings and grows its national footprint, Alignment
upholds its core values of leading with a serving heart and putting the senior
first. For more information, visit .

Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities Litigation Reform
Act of 1995, as amended. These forward-looking statements include statements
regarding our future growth and our financial outlook for the quarter and year
ending Dec. 31, 2026. Forward-looking statements are subject to risks and
uncertainties and are based on assumptions that may prove to be inaccurate,
which could cause actual results to differ materially from those expected or
implied by the forward-looking statements. Actual results may differ materially
from the results predicted, and reported results should not be considered as an
indication of future performance. Important risks and uncertainties that could
cause our actual results and financial condition to differ materially from those
indicated in the forward-looking statements include, among others, the
following: our ability to successfully execute our business plan and achieve
anticipated operational improvements and financial results; our ability to
manage changes in medical costs and healthcare utilization, and our ability to
accurately estimate, price for and manage such costs and utilization; our
ability to attract new members and enter new markets, including the need for
certain governmental approvals; our ability to achieve and maintain a high
rating for our plans on the Five Star Quality Rating System; our ability to
develop and maintain satisfactory relationships with care providers that service
our members; risks associated with being a government contractor, including
potential federal reductions in MA funding; changes in laws and regulations
applicable to our business model; risks related to our indebtedness; changes in
market or industry conditions and receptivity to our technology and services;
results of litigation or a security incident; and the impact of shortages of
qualified personnel and related increases in our labor costs. For a detailed
discussion of the risk factors that could affect our actual results, please
refer to the risk factors identified in our Annual Report on Form 10-K for the
year ended Dec. 31, 2025, our Quarterly Report on Form 10-Q for the quarter
ended September 30, 2026 and the other periodic reports we file with the SEC.
All information provided in this release and in the attachments is as of the
date hereof, and we undertake no duty to update or revise this information
unless required by law.
                                                                                
  Condensed Consolidated Balance                                                
  Sheets                                                                        
  (in thousands, except par value                                               
  and share amounts)                    September 30,          December 31,     
  (Unaudited)                                    2026                  2025     
 ────────────────────────────────────────────────────────────────────────────── 
  Assets                                                                        
  Current Assets:                                                               
  Cash and cash equivalents          $        727,694       $       575,817     
  Accounts receivable (less                                                     
  allowance for credit losses of              242,545               253,207     
  $699 at September 30, 2026 and                                                
  $833 at December 31, 2025)                                                    
  Investments - current                        15,260                28,413     
  Prepaid expenses and other                                                    
  current                                     192,808                94,140     
  assets                                                                        
  Total current assets                      1,178,307               951,577     
  Property and equipment, net                  66,439                64,251     
  Right of use asset, net                       7,206                 7,019     
  Goodwill                                     32,060                32,060     
  Intangible assets, net                        4,550                 4,550     
  Other assets                                  8,301                 6,329     
  Total assets                       $      1,296,863       $     1,065,786     
  Liabilities and Stockholders'                                                 
  Equity                                                                        
  Current Liabilities:                                                          
  Medical expenses payable           $        621,746       $       474,569     
  Accounts payable and accrued                 34,562                33,284     
  expenses                                                                      
  Accrued compensation                         32,744                49,013     
  Total current liabilities                   689,052               556,866     
  Long-term debt, net of debt                                                   
  issuance                                    324,497               323,176     
  costs                                                                         
  Long-term portion of lease                    6,202                 6,467     
  liabilities                                                                   
  Total liabilities                         1,019,751               886,509     
  Stockholders' Equity:                                                         
  Preferred stock, $0.001 par                                                   
  value; 100,000,000 shares                                                     
  authorized as of                                                              
  September 30, 2026 and December                   —                     —     
  31, 2025, respectively; no shares                                             
  issued and                                                                    
  outstanding as of September 30,                                               
  2026 and December 31, 2025                                                    
  Common stock, $0.001 par value;                                               
  1,000,000,000 shares authorized                                               
  as of                                                                         
  September 30, 2026 and December                                               
  31, 2025; 209,152,387 and                       209                   205     
  204,153,619 shares                                                            
  issued and outstanding as of                                                  
  September 30, 2026 and December                                               
  31, 2025,                                                                     
  respectively                                                                  
  Additional paid-in capital                1,245,996             1,188,089     
  Accumulated deficit                        (969,093  )         (1,009,017  )  
  Total stockholders' equity                  277,112               179,277     
  Total liabilities and                                                         
  stockholders'                      $      1,296,863       $     1,065,786     
  equity                                                                        
                                                                                
                                                                                
  Con…                                                                          
  Con…                                                                          
  Sta…                                                                          
  of                                                                            
  Ope…                                                                          
  (in                                                                           
  tho…                                                                          
  exc…  Three                              Nine                                 
  per   Mont…                              Months                               
  sha…  Ended                              Ended                                
  amo…  Sept…                              Septe…                               
  (Un…  30,                                30,                                  
  Rev…  2026                2025           2026                2025             
 ────────────────────────────────────────────────────────────────────────────── 
  Ear…  $      1,348…       $     983,…    $       3,90…       $     2,907…     
  pre…                                                                          
  Oth…         10,034             10,0…            27,6…             27,988     
  Tot…         1,358…             993,…            3,92…             2,935…     
  rev…                                                                          
  Exp…                                                                          
  Med…         1,217…             868,…            3,46…             2,570…     
  exp…                                                                          
  Sel…                                                                          
  gen…                                                                          
  and          136,3…             110,…            388,…             317,6…     
  adm…                                                                          
  exp…                                                                          
  Dep…                                                                          
  and           8,108             7,977            23,8…             22,574     
  amo…                                                                          
  Tot…         1,362…             986,…            3,87…             2,910…     
  exp…                                                                          
  Inc…                                                                          
  (lo…         (3,794  )          7,681            53,8…             25,036     
  from                                                                          
  ope…                                                                          
  Oth…                                                                          
  exp…                                                                          
  Int…          4,280             3,950            12,6…             11,850     
  exp…                                                                          
  Oth…                                                                          
  inc…              —                 —               (1  )             (89  )  
  net                                                                           
  Tot…                                                                          
  oth…          4,280             3,950            12,6…             11,761     
  exp…                                                                          
  Inc…                                                                          
  (lo…                                                                          
  bef…         (8,074  )          3,731            41,1…             13,275     
  inc…                                                                          
  tax…                                                                          
  Pro…                                                                          
  (be…                                                                          
  for             (22  )              2            1,269              3,247     
  inc…                                                                          
  tax…                                                                          
  Net                                                                           
  inc…  $      (8,052  )    $     3,729    $       39,9…       $     10,028     
  (lo…                                                                          
  Les…                                                                          
  Net                                                                           
  loss                                                                          
  att…              —                 —                —               (254  )  
  to                                                                            
  non…                                                                          
  int…                                                                          
  Net                                                                           
  inc…                                                                          
  (lo…                                                                          
  att…  $      (8,052  )    $     3,729    $       39,9…       $     10,282     
  to                                                                            
  Ali…                                                                          
  Hea…                                                                          
  Inc.                                                                          
  Net                                                                           
  inc…                                                                          
  (lo…                                                                          
  per                                                                           
  sha…                                                                          
  att…                                                                          
  to                                                                            
  Ali…                                                                          
  Hea…                                                                          
  Inc…                                                                          
  Bas…          (0.04  )           0.02             0.19               0.05     
  Dil…          (0.04  )           0.02             0.19               0.05     
  Wei…                                                                          
  com…                                                                          
  sha…                                                                          
  out…                                                                          
  Bas…         208,5…             199,…            207,…             197,0…     
  Dil…         208,5…             208,…            214,…             208,4…     
                                                                                
                                                                                
  Condensed                                                                     
  Consolidated                                                                  
  Statements of Cash                                                            
  Flows                                                                         
  (in thousands)                                                                
  (Unaudited)           Nine Months Ended                                       
  Operating             September 30,                                           
  Activities:           2026                                  2025              
 ────────────────────────────────────────────────────────────────────────────── 
  Net income            $                        39,924       $      10,028     
  Adjustments to                                                                
  reconcile net income                                                          
  to                                                                            
  net cash provided by                                                          
  operating                                                                     
  activities:                                                                   
  Provision for credit                              699                 548     
  loss                                                                          
  Gain on sale of                                                               
  property and                                       (1  )              (72  )  
  equipment                                                                     
  Depreciation and                               23,834              22,648     
  amortization                                                                  
  Amortization-invest…                             (478  )           (1,041  )  
  discount                                                                      
  Amortization-debt                               1,790               1,321     
  issuance costs                                                                
  Equity-based                                   49,680              48,967     
  compensation                                                                  
  Non-cash lease                                  1,439               1,178     
  expense                                                                       
  Changes in operating                                                          
  assets and                                                                    
  liabilities:                                                                  
  Accounts receivable                             9,963             (66,451  )  
  Prepaid expenses and                                                          
  other current                                 (98,668  )          (84,326  )  
  assets                                                                        
  Other assets                                       (9  )              (47  )  
  Medical expenses                              147,177             239,008     
  payable                                                                       
  Accounts payable and                            1,004              11,185     
  accrued expenses                                                              
  Accrued compensation                          (16,269  )            8,349     
  Lease liabilities                              (1,690  )             (993  )  
  Net cash provided by                                                          
  operating                                     158,395             190,302     
  activities                                                                    
  Investing                                                                     
  Activities:                                                                   
  Purchase of                                   (32,510  )          (45,194  )  
  investments                                                                   
  Sale of property and                                —                  75     
  equipment                                                                     
  Maturities of                                  46,135              57,995     
  investments                                                                   
  Sale of business                                    —               1,065     
  Acquisition of                                                                
  property and                                  (25,952  )          (21,752  )  
  equipment                                                                     
  Net cash used in                              (12,327  )           (7,811  )  
  investing activities                                                          
  Financing                                                                     
  Activities:                                                                   
  Debt issuance costs                            (2,397  )              (26  )  
  Proceeds from stock                             8,231               2,771     
  option exercises                                                              
  Net cash provided by                                                          
  financing                                       5,834               2,745     
  activities                                                                    
  Net increase in cash                          151,902             185,236     
  Cash, cash                                                                    
  equivalents and                                                               
  restricted                                    577,937             434,942     
  cash at beginning of                                                          
  period                                                                        
  Cash, cash                                                                    
  equivalents and                                                               
  restricted            $                       729,839       $     620,178     
  cash at end of                                                                
  period                                                                        
  Supplemental                                                                  
  disclosure of cash                                                            
  flow                                                                          
  information:                                                                  
  Cash paid for         $                         7,013       $       6,740     
  interest                                                                      
  Supplemental                                                                  
  non-cash investing                                                            
  and                                                                           
  financing                                                                     
  activities:                                                                   
  Acquisition of                                                                
  property in accounts  $                             9       $          79     
  payable                                                                       
                                                                                
The following table provides a reconciliation of cash, cash equivalents and
restricted cash reported within the consolidated balance sheets to the total
above:
                                                                         
                                      September 30,       September 30,  
                                               2026                2025  
 ─────────────────────────────────────────────────────────────────────── 
  Cash and cash equivalents        $        727,694    $        618,067  
  Restricted cash in other assets             2,145               2,111  
  Total                            $        729,839    $        620,178  
                                                                         
Non-GAAP Financial Measures

Certain of these financial measures are considered “non-GAAP” financial measures
within the meaning of Item 10 of Regulation S-K promulgated by the SEC. We
believe that non-GAAP financial measures provide an additional way of viewing
aspects of our operations that, when viewed with the GAAP results, provide a
more complete understanding of our results of operations and the factors and
trends affecting our business. These non-GAAP financial measures are also used
by our management to evaluate financial results and to plan and forecast future
periods. However, non-GAAP financial measures should be considered as a
supplement to, and not as a substitute for, or superior to, the corresponding
measures calculated in accordance with GAAP. Non-GAAP financial measures used by
us may differ from the non-GAAP measures used by other companies, including our
competitors. To supplement our consolidated financial statements presented on a
GAAP basis, we disclose the following non-GAAP measures: Medical Benefits Ratio,
Adjusted EBITDA and Adjusted Gross Profit as these are performance measures that
our management uses to assess our operating performance. Because these measures
facilitate internal comparisons of our historical operating performance on a
more consistent basis, we use these measures for business planning purposes and
in evaluating acquisition opportunities.

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that we define as net income
(loss) before interest expense, income taxes, depreciation and amortization
expense, certain litigation costs, gains or losses on sale of property and
equipment, and equity-based compensation expense.

Adjusted EBITDA should not be considered in isolation of, or as an alternative
to, measures prepared in accordance with GAAP. There are a number of limitations
related to the use of Adjusted EBITDA in lieu of net income (loss), which is the
most directly comparable financial measure calculated in accordance with GAAP.

Our use of the term Adjusted EBITDA may vary from the use of similar terms by
other companies in our industry and accordingly may not be comparable to
similarly titled measures used by other companies.

Medical Benefits Ratio (MBR)

We calculate our MBR by dividing total medical expenses, excluding depreciation,
and medical equity-based compensation, by total revenues in a given period.

Adjusted Gross Profit

Adjusted gross profit is a non-GAAP financial measure that we define as income
(loss) from operations before depreciation and amortization, medical equity-
based compensation expense, and selling, general, and administrative expenses.

Adjusted gross profit should not be considered in isolation of, or as an
alternative to, measures prepared in accordance with GAAP. There are a number of
limitations related to the use of adjusted gross profit in lieu of income (loss)
from operations, which is the most directly comparable financial measure
calculated in accordance with GAAP.

Our use of the term adjusted gross profit may vary from the use of similar terms
by other companies in our industry and accordingly may not be comparable to
similarly titled measures used by other companies.

Investor Contact
Harrison Zhuo

Media Contact
Jerry Slowey
[email protected]

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ALHC/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.